Faes Farma (FAE) Q2 2026 earnings summary

Executive summary

• Revenue increased 27% year-over-year to €391.5 million, driven by international expansion, integration of SIFI and Edol, and diversification into ophthalmology, which now represents 16% of group revenue.

• EBITDA rose 24% to €90.8 million (28% excluding restructuring costs), reflecting robust operational performance despite integration expenses.

• Net profit attributable to shareholders increased 9% to €57 million, with profit before taxes up 8%.

• Strategic focus on international markets, especially Latin America, and continued portfolio diversification and innovation.

• Integration of SIFI and Edol strengthened the ophthalmology segment and international presence.

Financial highlights

• Revenue reached €391.5 million, up 27% year-over-year; ordinary revenue was €382.9 million (+29%).

• EBITDA totaled €90.8 million, up 24% (28% adjusted for restructuring costs); EBIT was €71.0 million (+15%).

• Net profit was €57 million, a 9% increase year-over-year.

• Organic gross profit grew 31% to €270 million; gross margin was €269.6 million (+30.7%).

• Free cash flow after financial payments and taxes was €18.9 million.

Outlook and guidance

• Full-year 2026 guidance reaffirmed: revenue growth of 17–19% and EBITDA growth of 28–31% expected.

• Net debt to EBITDA ratio expected to remain below 2x by year-end.

• Double-digit growth in Latin America anticipated to continue, supported by new product launches and regulatory approvals.

• Focus for H2 2026 on commercial execution, further integration of SIFI and Edol, and innovation in ophthalmology.

• No further restructuring costs expected for the remainder of the year.